titan pharmaceuticals inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. the company's lead product is probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. it was approved by the u.s. food and drug administration in may 2016 and is being commercialized in the u.s. by partner braeburn pharmaceuticals. probuphine employs titan's proprietary drug delivery system proneura™, which is capable of delivering sustained, consistent levels of medication for up to 12 months. the proneura technology has the potential to be used in developing products for treating other chronic conditions such as parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.
Company profile
Ticker
TTNP, TTNPW
Exchange
Website
CEO
Sunil Bhonsle
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
943171940
TTNP stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
3 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
1 Apr 24
8-K
Unregistered Sales of Equity Securities
21 Mar 24
8-K
Other Events
8 Feb 24
8-K
Other Events
25 Jan 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
8 Jan 24
8-K
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio
28 Dec 23
DEF 14A
Definitive proxy
28 Nov 23
Transcripts
TTNP
Earnings call transcript
2020 Q3
16 Nov 20
TTNP
Earnings call transcript
2020 Q2
14 Aug 20
TTNP
Earnings call transcript
2020 Q1
15 May 20
TTNP
Earnings call transcript
2019 Q4
30 Mar 20
TTNP
Earnings call transcript
2019 Q3
14 Nov 19
TTNP
Earnings call transcript
2019 Q2
14 Aug 19
TTNP
Earnings call transcript
2019 Q1
15 May 19
TTNP
Earnings call transcript
2018 Q4
2 Apr 19
TTNP
Earnings call transcript
2018 Q3
14 Nov 18
TTNP
Earnings call transcript
2018 Q1
16 May 18
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.11 mm | 8.11 mm | 8.11 mm | 8.11 mm | 8.11 mm | 8.11 mm |
Cash burn (monthly) | (no burn) | (no burn) | 687.00 k | 663.08 k | 611.67 k | 535.42 k |
Cash used (since last report) | n/a | n/a | 4.70 mm | 4.54 mm | 4.19 mm | 3.67 mm |
Cash remaining | n/a | n/a | 3.40 mm | 3.57 mm | 3.92 mm | 4.44 mm |
Runway (months of cash) | n/a | n/a | 5.0 | 5.4 | 6.4 | 8.3 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 26 |
Opened positions | 4 |
Closed positions | 4 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 545.25 mm |
Total shares | 1.48 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
TFC Truist Financial | 625.09 k | $403.93 mm |
L1 Capital Global Opportunities Master Fund | 494.72 k | $505.00 k |
Renaissance Technologies | 135.61 k | $88.00 k |
Vanguard | 82.05 k | $53.02 mm |
Geode Capital Management | 63.97 k | $41.45 mm |
STT State Street | 38.29 k | $24.81 mm |
Citadel Advisors | 29.68 k | $19.23 mm |
Intracoastal Capital | 3.33 k | $0.00 |
Tower Research Capital | 1.57 k | $1.02 mm |
Level Financial Advisors | 987.00 | $638.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Choon Hau Choong | Common Stock | Conversion | Acquire C | No | No | 0 | 54,132 | 0.00 | 3,802,100 |
18 Mar 24 | Choon Hau Choong | Convertible Promissory Note Common Stock | Conversion | Dispose C | No | No | 9.32 | - | 500.00 k | 0 |
25 Oct 23 | Avraham Ben-Tzvi | Common Stock | Grant | Acquire A | No | No | 0 | 16,250 | 0.00 | 66,250 |
25 Oct 23 | Katherine Beebe | Common Stock | Grant | Acquire A | No | No | 0 | 16,250 | 0.00 | 66,250 |
News
12 Health Care Stocks Moving In Friday's After-Market Session
19 Apr 24
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
8 Apr 24
The Sire Group Ltd Says Expect To Propose To Titan Pharmaceuticals Inc A Business Combination With KE Sdn. Bhd
5 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Mar 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
26 Mar 24